Prolonged remission was observed in 72% of patients with systemic lupus erythematosus (SLE) who were treated with a consistent 200 mg daily dose of hydroxychloroquine. The mean weight-adjusted ...

A new study found a connection between lower doses of hydroxychloroquine (HCQ) and increased risk of hospitalization in people with active systemic lupus erythematosus (SLE). HCQ (known commercially ...

A cohort study of more than 3,000 persons who received hydroxychloroquine for 5 or more years with guideline-recommended serial retinopathy screening found that the overall risk for incident ...

The mutagenic potential of hydroxychloroquine has not been evaluated. However, chloroquine has been shown to be a catalytic inhibitor of DNA repair enzymes (topoisomerase II) and to produce weak ...

Patients who took hydroxychloroquine had an overall risk of hydroxychloroquine retinopathy of 8.6% after 15 years. A higher dose of hydroxychloroquine was associated with a greater risk of incident ...

Hydroxychloroquine, initially a malaria treatment, may help with autoimmune conditions like RA by modulating the immune system and reducing inflammation. RA symptoms may improve within 2 months of ...